{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:30:47Z","timestamp":1790271047999,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics"},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10637-025-01536-5","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:34:17Z","timestamp":1745987657000},"page":"582-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Retrospective analysis of clinical features of pembrolizumab induced psoriasis"],"prefix":"10.1007","volume":"43","author":[{"given":"Ming","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"Pt 2","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"HM Arafat","year":"2024","unstructured":"Arafat HM (2024) A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol 143(Pt 2):113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"1","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV (2021) Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text]. J Cutan Med Surg 25(1):59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","volume":"41","author":"M Bhardwaj","year":"2022","unstructured":"Bhardwaj M, Chiu MN, Pilkhwal SS (2022) Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol 41(1):73\u201390. https:\/\/doi.org\/10.1080\/15569527.2022.2034842","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamadermatol.2024.4129","volume":"161","author":"SY To","year":"2025","unstructured":"To SY, Lee CH, Chen YH, Hsu CL, Yang HW, Jiang YS, Wen YL, Chen IW, Kao LT (2025) Psoriasis Risk With Immune Checkpoint Inhibitors. JAMA Dermatol 161(1):31\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4129","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1536_CR6","doi-asserted-by":"publisher","first-page":"e003066","DOI":"10.1136\/jitc-2021-003066","volume":"9","author":"BR Halle","year":"2021","unstructured":"Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK et al (2021) Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer 9(10):e003066. https:\/\/doi.org\/10.1136\/jitc-2021-003066","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide. Multicenter Cohort Study Arthritis Rheumatol 71(12):2100\u20132111. https:\/\/doi.org\/10.1002\/art.41068","journal-title":"Multicenter Cohort Study Arthritis Rheumatol"},{"issue":"2","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2):377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.36849\/JDD.7226","volume":"23","author":"M Kaiser","year":"2024","unstructured":"Kaiser M, Jaalouk D, Issa NT (2024) Psoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1. J Drugs Dermatol 23(2):103\u2013104. https:\/\/doi.org\/10.36849\/JDD.7226","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789. https:\/\/doi.org\/10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"1082084","DOI":"10.3389\/fimmu.2022.1082084","volume":"13","author":"M Gazzano","year":"2022","unstructured":"Gazzano M, Parizot C, Psimaras D, Vozy A, Baron M, Abbar B et al (2022) Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. Front Immunol 13:1082084. https:\/\/doi.org\/10.3389\/fimmu.2022.1082084","journal-title":"Front Immunol"},{"key":"1536_CR12","doi-asserted-by":"publisher","first-page":"1346687","DOI":"10.3389\/fimmu.2024.1346687","volume":"15","author":"M Morelli","year":"2024","unstructured":"Morelli M, Carbone ML, Scaglione GL, Scarponi C, Di Francesco V, Pallotta S et al (2024) Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors. Front Immunol 15:1346687. https:\/\/doi.org\/10.3389\/fimmu.2024.1346687","journal-title":"Front Immunol"},{"issue":"10275","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754\u2013766. https:\/\/doi.org\/10.1016\/S0140-6736(21)00184-7","journal-title":"Lancet"},{"issue":"10281","key":"1536_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN (2021) Psoriasis. Lancet 397(10281):1301\u20131315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"issue":"2","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","volume":"35","author":"J Dulos","year":"2012","unstructured":"Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W et al (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35(2):169\u2013178. https:\/\/doi.org\/10.1097\/CJI.0b013e318247a4e7","journal-title":"J Immunother"},{"key":"1536_CR16","doi-asserted-by":"publisher","first-page":"7346030","DOI":"10.1155\/2016\/7346030","volume":"2016","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang L, Yang H, Yuan W, Ren J, Bai Y (2016) Activated circulating T follicular helper cells are associated with disease severity in patients with psoriasis. J Immunol Res 2016:7346030. https:\/\/doi.org\/10.1155\/2016\/7346030","journal-title":"J Immunol Res"},{"issue":"6","key":"1536_CR17","doi-asserted-by":"publisher","first-page":"e829","DOI":"10.1016\/j.cllc.2021.04.002","volume":"22","author":"H Furuta","year":"2021","unstructured":"Furuta H, Kato S, Masago K, Hida T (2021) Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors. Clin Lung Cancer 22(6):e829\u2013e832. https:\/\/doi.org\/10.1016\/j.cllc.2021.04.002","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","volume":"86","author":"R Tanaka","year":"2017","unstructured":"Tanaka R, Okiyama N, Okune M, Ishitsuka Y, Watanabe R, Furuta J et al (2017) Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity. J Dermatol Sci 86(1):71\u201373. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.12.019","journal-title":"J Dermatol Sci"},{"issue":"3","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/jid.2008.294","volume":"129","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Kawaguchi M, Fujishima S, Ogura M, Matsukura S, Takeuchi H et al (2009) Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 129(3):650\u2013656. https:\/\/doi.org\/10.1038\/jid.2008.294","journal-title":"J Invest Dermatol"},{"issue":"19","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"12","key":"1536_CR21","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA et al (2020) Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol 6(12):1952\u20131956. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012","journal-title":"JAMA Oncol"},{"issue":"6","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J et al (2020) Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med 172(6):369\u2013380. https:\/\/doi.org\/10.7326\/M19-3369","journal-title":"Ann Intern Med"},{"issue":"10","key":"1536_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","volume":"158","author":"MK Yan","year":"2022","unstructured":"Yan MK, Wang C, Wolfe R, Mar VJ, Wluka AE (2022) Association Between Low-Dose Methotrexate Exposure and Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol 158(10):1157\u20131166. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3337","journal-title":"JAMA Dermatol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01536-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:07:15Z","timestamp":1753934835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01536-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}